Literature DB >> 26806538

The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study.

K M Prakash1,2,3, N V Nadkarni4, W-K Lye4, M-H Yong1, E-K Tan1,2,3.   

Abstract

BACKGROUND AND
PURPOSE: Non-motor symptoms (NMSs) are common amongst patients with Parkinson's disease (PD); however, little is known about their influence on the health-related quality of life (QoL) over a defined follow-up period. The study was aimed to establish the impact of NMSs on the QoL of patients with PD over a 2-year follow-up period.
METHOD: A total of 227 newly referred PD patients were prospectively recruited between 2013 and 2014. The Non-Motor Symptoms Scale was used to evaluate NMSs burden whilst QoL was assessed with the Parkinson's Disease Questionnaire-39 items. Motor disabilities were assessed using the Part III (motor) Unified Parkinson's Disease Rating Scale (UPDRSm).
RESULTS: The mean age was 64.37 (10.18) years; 59.9% were males and a majority (89.0%) were ethnic Chinese. Almost 65% were unemployed and 84.6% had attained no more than secondary level of education. In the univariate analysis, total NMSs burden, age, gender, subsequent visit, Hoehn and Yahr staging, disease duration and UPDRSm score were individually predictive of change in the Parkinson's Disease Questionnaire Summary Index score from baseline to follow-up visit. However, in the multivariate analysis, total NMSs burden significantly predicted the QoL scores whilst motor scores did not. Specifically, NMS domains 2 (sleep/fatigue), 3 (mood/apathy) and 5 (attention/memory) were most significantly predictive of QoL change.
CONCLUSION: Unlike motor disabilities, NMSs burden, in particular sleep, mood and attention, have a significant impact on the QoL of PD patients over a 2-year follow-up period.
© 2016 EAN.

Entities:  

Keywords:  Parkinson's disease; longitudinal study; non-motor symptoms; quality of life

Mesh:

Year:  2016        PMID: 26806538     DOI: 10.1111/ene.12950

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  55 in total

1.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

2.  Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers.

Authors:  Rosella Ciurleo; Francesco Corallo; Lilla Bonanno; Viviana Lo Buono; Giuseppe Di Lorenzo; Roberta Versaci; Cettina Allone; Rosanna Palmeri; Placido Bramanti; Silvia Marino
Journal:  J Neurol       Date:  2018-06-27       Impact factor: 4.849

Review 3.  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors:  Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal:  Nat Rev Drug Discov       Date:  2018-09-28       Impact factor: 84.694

4.  Do cognition and other non-motor symptoms decline similarly among patients with Parkinson's disease motor subtypes? Findings from a 5-year prospective study.

Authors:  L Arie; Talia Herman; S Shema-Shiratzky; N Giladi; J M Hausdorff
Journal:  J Neurol       Date:  2017-09-06       Impact factor: 4.849

5.  New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease.

Authors:  Michael A Kelberman; Elena M Vazey
Journal:  Curr Pharmacol Rep       Date:  2016-09-28

Review 6.  Palliative Care for Parkinson's Spectrum Disorders: an Emerging Approach.

Authors:  Maya Katz
Journal:  Neurotherapeutics       Date:  2021-01-13       Impact factor: 7.620

7.  Complex therapies for advanced Parkinson's disease: what is the role of doctor-patient communication?

Authors:  Elisa Montanaro; Carlo Alberto Artusi; Maurizio Zibetti; Leonardo Lopiano
Journal:  Neurol Sci       Date:  2019-06-28       Impact factor: 3.307

Review 8.  Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.

Authors:  Eva Schaeffer; Daniela Berg
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

9.  Patient-centered integrated healthcare improves quality of life in Parkinson's disease patients: a randomized controlled trial.

Authors:  Carsten Eggers; R Dano; J Schill; G R Fink; M Hellmich; L Timmermann
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

10.  Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS).

Authors:  Pablo Martinez-Martin; Anette Schrag; Daniel Weintraub; Alexandra Rizos; Carmen Rodriguez-Blazquez; Kallol Ray Chaudhuri
Journal:  Mov Disord Clin Pract       Date:  2019-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.